Aidan T. Morrell

Aidan T. Morrell

Auto-generated profile, based on publicly available information

Aidan T. Morrell

Orthopaedics, Oregon Health & Science University, Portland, Oregon, USA

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 June 2021 in Journal of Bone and Joint Surgery
Verified
Journal Article
Closed access
AMAidan T. Morrell
Aidan T. Morrell
DLDaniel R. Layon
Daniel R. Layon
MSMichael J. Scott
Michael J. Scott
SKStephen L. Kates
Stephen L. Kates
GGGregory J. Golladay
Gregory J. Golladay
NPNirav K. Patel
Nirav K. Patel
Background: Enhanced Recovery After Surgery (ERAS) has become increasingly implemented to reduce costs, to increase efficiency, and to optimize patient outcomes after a surgical procedure. This study aimed to systematically review the effect of ERAS after primary elective total hip arthroplasty (THA) or total knee arthroplasty (TKA) on hospital length of stay, total procedure-related morbidity, and readmission. Methods: A systematic review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines and with guidance from the Cochrane Handbook for Systematic Reviews of Interventions. MEDLINE, Embase, and Cochrane databases were searched from inception (1946 for MEDLINE and 1974 for Embase; Cochrane is a composite of multiple databases and thus does not report a standard inception date) until January 15, 2020. Prospective nonrandomized cohort studies and randomized controlled trials comparing adult patients undergoing elective primary THA or TKA with ERAS or traditional protocols were included. Articles examining outpatient, nonelective, or revision surgical procedures were excluded. Two reviewers independently assessed the risk of bias and extracted data. The primary outcome was length of stay. The secondary outcomes included total procedure-related morbidity and readmission. Results: Of the 1,018 references identified (1,017 identified through an electronic search and 1 identified through a manual search), 9 individual studies met inclusion criteria. Data were reported from 7,789 participants, with 2,428 receiving ERAS and 5,361 receiving traditional care. Narrative synthesis was performed instead of meta-analysis, given the presence of moderate to high risk of bias, wide variation of ERAS interventions, and inconsistent methods for assessing and reporting outcomes among included studies. Adherence to ERAS protocols consistently reduced hospital length of stay. Few studies demonstrated reduced total procedure-related morbidity, and there was no significant effect on readmission rates. Conclusions: ERAS likely reduced the length of stay after primary elective THA and TKA, with a more pronounced effect in selected healthier patient populations. We found minimal to no impact on perioperative morbidity or readmission. The quality of existing evidence was limited because of study heterogeneity and a significant risk of bias. Further high-quality research is needed to definitively assess the impact of ERAS on total joint arthroplasty. Level of Evidence: Therapeutic Level II. See Instructions for Authors for a complete description of levels of evidence.

1 December 2019 in Arthroplasty Today
Verified
Journal Article
Open access
AMAidan T. Morrell
Aidan T. Morrell
GGGregory J. Golladay
Gregory J. Golladay
SKStephen L. Kates
Stephen L. Kates
Periprosthetic joint infection (PJI) is a devastating complication of total hip arthroplasty (THA). Patient optimization represents an important target for PJI prevention. Unfortunately, best practice screening guidelines are not consistently followed by all surgeons. Our study aimed to determine both the degree and the effect that compliance with our institutional preoperative surgical selection criteria had on PJI rates for patients undergoing elective primary THA. A retrospective review was conducted on 455 elective primary THA procedures performed at an academic tertiary care center over a 2-year period. Institutional preoperative surgical selection criteria included the following: body mass index ≤40 kg/m2, hemoglobin A1c ≤7.5%, hemoglobin ≥12 g/dL, albumin ≥3.5 g/dL, no smoking within 30 days prior to surgery, and completion of a decolonization protocol if a nasal polymerase chain reaction was positive for Staphylococcus aureus. PJI was assessed for a minimum 1-year follow-up using Musculoskeletal Infection Society criteria from 2011. Rates of compliance and PJI were compared using a chi-squared test. Surgeon compliance with institutional preoperative selection criteria was 62.4% and ranged from 0.0% to 83.9%. Five of 455 patients developed a PJI. The total PJI rate was 1.1%. The compliant patient cohort had a PJI rate of 0.0%, while the noncompliant cohort had a PJI rate of 2.9% (P = .0038). This study identified a statistically significant decrease in PJI rates among patients who met all preoperative screening criteria.

1 September 2020 in Arthroplasty Today
Verified
Journal Article
Open access
DLDaniel R. Layon
Daniel R. Layon
WJWilliam L. Johns
William L. Johns
AMAidan T. Morrell
Aidan T. Morrell
RPRobert Perera
Robert Perera
NPNirav K. Patel
Nirav K. Patel
SKStephen L. Kates
Stephen L. Kates
There has been recent increased focus on the importance of modifiable risk factors that can affect the risk of potentially avoidable complications such as prosthetic joint infection (PJI). We aimed to assess the relationship between adherence to a preoperative optimization protocol at our institution and its influence on the rate of PJI after primary and revision total knee arthroplasty (TKA). A single-institution, retrospective study was conducted on all elective primary and revision TKAs performed over a 2-year period. PJI was diagnosed using the 2011 Musculoskeletal Infection Society criteria. Surgical outcomes and PJI were assessed relative to adherence to preoperative optimization criteria. Compliance was set as a binary variable with any case that did not meet all criteria deemed noncompliant. A total of 669 TKAs met inclusion criteria, including 510 primary and 159 revision TKAs. Overall compliance was 61.3%. There were 26 PJIs (3.9%) in total. The PJI rate was 1.2% (6) among primary and 14.4% (20) among revision TKAs. The rate of PJI among cases that met the preoperative optimization criteria was 2.4% (5), and the rate among cases that did not was 6.2% (21) (P < .05). Adherence to preoperative optimization criteria may decrease the incidence of PJI after primary and revision TKA, but further study is needed to confirm the findings of this study.

22 September 2020 in Injury
Verified
Journal Article
Closed access
PDF file
DLDaniel Layon
Daniel Layon
AMAidan T. Morrell
Aidan T. Morrell
CLChristopher Lee
Christopher Lee

1 June 2021 in Arthroplasty Today
Verified
Journal Article
Open access
AMAidan T. Morrell
Aidan T. Morrell
SKStephen L. Kates
Stephen L. Kates
LLLaura A. Lahaye
Laura A. Lahaye
DLDaniel R. Layon
Daniel R. Layon
NPNirav K. Patel
Nirav K. Patel
GGGregory J. Golladay
Gregory J. Golladay

8 April 2025 in BMJ Open
Verified
Journal Article
Open access
AMAidan Morrell
Aidan Morrell
SSSteven Shelofsky
Steven Shelofsky
HHHannah Hoffman
Hannah Hoffman
CMCole McCallister
Cole McCallister
THThomas W Huff
Thomas W Huff
RKRyland P Kagan
Ryland P Kagan
Introduction: Patients with poor perioperative glycaemic control after total joint arthroplasty are at an increased risk of complications, mortality, delayed return to function and increased costs of care. Although correction of hyperglycaemia has been shown to improve patient outcomes, there is a lack of consensus regarding optimal perioperative glucose management after total joint replacement surgery. This pilot study aims to assess the feasibility of performing a multicentre randomised controlled trial to investigate the effect of perioperative metformin use on glycaemic control in the setting of total joint arthroplasty. Methods and analysis: This blinded, placebo-controlled, pilot randomised controlled trial will enrol 40 participants aged 18–99 years undergoing total hip or knee arthroplasty at a single academic tertiary centre. Patients will be randomly allocated to two groups of 20 participants each and will receive metformin or a placebo, respectively, for 2 weeks preoperatively, continued on the day of surgery, and up to 2 days postoperatively. The primary outcome is a composite of four endpoints to assess study feasibility: timely recruitment, timely study drug administration, protocol adherence and retention. Secondary outcomes include perioperative glycaemic variability, sliding scale insulin utilisation, hospital length of stay and 90-day rates of infection, mortality and readmission. Analyses will be on an intention-to-treat basis. Ethics and dissemination: The protocol was approved by Oregon Health & Science University Institutional Review Board, STUDY00025798. Written informed consent will be obtained for study participation. Findings will be disseminated via publication in peer-reviewed journals and conference presentations. Trial registration number: NCT06280274.